Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary

March 12, 2026

OTC Pink Market US Health Care Biotechnology earnings 28 min

Earnings Call Speaker Segments

Ed Berg

executive
#1

Hello, everyone, and welcome to our call this afternoon. We're joined today from Vaxart by Steven Lo, who serves as our Chief Executive Officer; Dr. Sean Tucker, our Founder and Chief Scientific Officer; Dr. James Cummings, our Chief Medical Officer; and Jeroen Grasman, our Chief Financial Officer. A quick note before we begin: during this conference call, Vaxart may issue forward-looking statements. These cover things such as the company's financial results, financial guidance, future business strategies and operations, and progress on product development and regulatory matters — including statements about clinical trials that are underway or planned. The outcomes we actually achieve might end up substantially different from what these forward-looking statements suggest, due to several significant considerations — such as the unpredictability that comes with clinical development and the regulatory pathway, plus additional risks outlined under the Risk Factors heading in Vaxart's latest annual report on Form 10-K, as well as in other periodic filings made with the SEC. Vaxart assumes no duty to revise any forward-looking statements once this call has taken place. At this point I'll pass things over to Steven Lo. Steve?

Steve Lo

executive
#2

Thank you, Ed, and I appreciate everyone taking the time to be with us this afternoon. I'll kick off today's call by walking through a number of business updates, after which we'll hand things over to James and Sean for the newest program developments. Following that, Jeroen will provide an update on the financial results for our fourth quarter and the full year 2025, and then I'll offer a few closing remarks before we take your questions. Turning now to recent operational news. Vaxart hit a number of important milestones lately. To start, we formed a partnership with Dynavax covering our oral COVID-19 vaccine candidate. Next, we grew our clinical evidence base by publishing the full data set from the clinical study of our oral norovirus vaccine candidate in lactating mothers. And third, we keep managing our costs, which is shown by our signing of a lease termination agreement that will deliver meaningful savings by letting us end one of our leases ahead of schedule. As we announced in November 2025, we formed a partnership with Dynavax for our oral COVID-19 vaccine candidate. When that announcement was made, we got a $25 million upfront payment plus a $5 million equity investment, made at a premium to the closing price. This partnership offers strong validation of the potential of our oral vaccine platform, coming from a company with a demonstrated track record of developing and commercializing innovative vaccines. It also lengthens our cash runway. In late December 2025, Sanofi announced it would acquire Dynavax, a deal that officially closed on February 10 of this year. Sanofi is a worldwide leader in vaccines, and we're happy to be moving ahead with Dynavax as a Sanofi company. During the past 3 months, we've built a highly productive working relationship with our collaborators, and our focus stays on executing and completing the Phase IIb trial and delivering those results. Per the terms of our agreement, we'll get an additional $50 million if Dynavax chooses to continue development after submission of the Phase IIb data to the FDA. We also remain eligible for as much as $195 million in future regulatory milestones, $425 million in sales milestones and tiered royalties in the low- to mid-teens. This agreement represents a total potential value of up to $700 million in license, regulatory and milestone fees, tiered royalties and the equity investment. Earlier, we talked about our commitment to managing our financial resources for maximum effect; that includes pursuing revenue-generating business development agreements, like our partnership with Dynavax. It also includes seeking ways to lower our operating costs without hurting our ability to realize the potential value of our pipeline programs and platform technology. To that end, in December 2025, we signed a lease termination agreement with one of our landlords, which will let us terminate one of our leases on May 15, 2026, instead of March 31, 2029. This earlier termination will help lower our operating expenses and improve our ability to concentrate our financial resources on advancing our lead programs. At this point, I'll hand things over to Dr. Cummings, who will share where our clinical programs currently stand. James?

James Cummings

executive
#3

Appreciate that, Steve, and I want to thank everybody for being on the call today. Just to remind you, we've got a Phase IIb study underway right now, testing our oral COVID-19 vaccine candidate against an mRNA vaccine. The main goal of this trial is the relative efficacy of our oral pill vaccine versus the mRNA vaccine over 12 months following vaccination. Efficacy will be assessed by the trial for symptomatic as well as asymptomatic disease, along with systemic and mucosal immune induction and adverse events within each cohort. As most of you know, this study was originally set up to enroll 400 subjects into a sentinel cohort meant to evaluate the safety of our oral COVID-19 vaccine candidate, plus 10,000 subjects into the KP.2 cohort, with half getting our oral candidate and the other half getting an injected mRNA vaccine; in October 2025 we made an announcement, and BARDA modified the work order for this trial and is now funding follow-up for the roughly 5,400 subjects who were enrolled before a stop work order that BARDA issued in August 2025. That total consists of 400 subjects in the sentinel cohort and approximately 5,000 subjects in the KP.2 cohort who were enrolled in this trial. With COVID-19 still affecting global health, the demand for next-generation solutions is obviously still there; we anticipate reporting 12-month top line data from the 400 participant sentinel cohort early in the second quarter of 2026. When this actually happens will be worked out together with BARDA. As we've said before, our contract obligates us to consult with BARDA and obtain its approval on the timing and content of any press releases tied to this trial. Once we announce, we expect to include data on the primary safety endpoints for the sentinel cohort, plus initial data on efficacy measures. Keep in mind that the 400-person sentinel cohort was created specifically to evaluate safety and was never intended to establish efficacy. Efficacy insights will come from the data on the 5,000 subjects in the KP.2 cohort, and we anticipate reporting those late in the fourth quarter of 2026. Once again, when this actually happens will be worked out together with BARDA. As I've said in the past, we think the results of this trial will deliver important insights into the potential of our COVID-19 candidate and into our oral pill vaccine platform technology. The first of those matters greatly for moving the COVID-19 candidate's development forward, while the second should help guide development of our other pipeline assets. One such asset is our oral norovirus vaccine candidate. As Steve noted when the call began, in January 2026 we published the full data set from the clinical study of our oral norovirus vaccine candidate in lactating mothers in npj vaccines. That Phase I multicenter, randomized, double-blind, placebo-controlled, single-dose dose ranging study was intended to assess the safety, tolerability and immunogenicity of an orally administered bivalent GI.1/GII.4 norovirus vaccine in healthy lactating women. Safety and reactogenicity, along with breast milk and serum norovirus-specific IgA, were the study's primary outcomes. Let me walk through what we shared in the press release dated January 15, 2026, which announced that this data had been published. In the trial, 76 women between 18 and 43 years old were enrolled across 5 sites located in South Africa. They were randomly assigned to receive either a high dose or a medium dose of the vaccine, or a placebo. According to the findings, the vaccine proved safe and was well tolerated, and reports of mild or moderate adverse events, or AEs, came in at similar rates for the placebo arm and for both vaccine arms. Furthermore, no AEs above Grade 2 were reported. When it came to serum and breast milk IgA measured at day 29 following vaccination, the results indicated that norovirus-specific IgA in serum increased by an average of 5.6-fold against GI.1 and 4.7-fold against GII.4 among those given the high dose. In breast milk, norovirus-specific IgA went up by an average of fourfold against GI.1 and sixfold against GII.4 in the high-dose group. Every one of those breast milk increases reached statistical significance and was sustained all the way through day 180. The passive transfer of IgA to infants was an exploratory analysis, yet the outcome was highly compelling. The data reveal a consistent pattern of elevated GI.1 and GII.4 specific IgA in stool samples from the paired infants of vaccinated women at days 29 and 60, and they show a positive association linking IgA levels in maternal breast milk with those in infant stool, which backs the hypothesis that mucosal immunity is passively transferred. This antibody transfer that we observed points to the possibility that the oral norovirus vaccine could open up a novel way to deliver mucosal antiviral immunity to infants, or to those who are highly susceptible to norovirus infection. Kids younger than 5 years of age can develop severe illness from norovirus infection, especially in areas with limited resources. Being able to shield infants from severe norovirus-associated disease via oral vaccination and other means could deliver important public health benefits, both in terms of lowering individual morbidity and mortality and in terms of curbing the spread of a virus that is highly contagious. These study results strengthen the expanding body of evidence that supports the promise of our oral norovirus vaccine candidate and its ability to address a substantial unmet public health need, given that no vaccine for norovirus has been approved to date. I'd also like to remind you of another piece of evidence from our norovirus program, which we reported back in June 2025. That was the outcome of a Phase I trial designed to compare our second-generation vaccine constructs with the original first-generation oral vaccine, in order to determine whether the new formulation generated stronger immunity. As we reported, the study demonstrated that the second-generation constructs yielded significantly higher antibody responses — a 141% increase for 1 strain and a 94% increase for the other — relative to the first-generation vaccines. These data help move forward not just our norovirus program, but our oral pill vaccine platform more broadly. The technology behind our second-generation norovirus constructs has likewise been built into the other programs in our pipeline. And given what the head-to-head study showed, we believe this will boost the immunogenicity of our COVID-19, seasonal and pandemic flu, and HPV vaccine candidates. I'll hand things over now to Dr. Sean Tucker, who will bring us up to speed on the norovirus program and share a bit about what's happening in our preclinical research. Sean?

Sean Tucker

executive
#4

Thanks, James. We're putting together a strong set of data that backs the promise of our oral norovirus vaccine program, and expanding that dataset is central to how we plan to push our business development work forward on this promising asset. As we've said before, we're ready to kick off the next clinical trial for our second-generation norovirus vaccine constructs in 2026, assuming we secure a partnership or other funding. As part of how we generate evidence, we've been looking into how the GII.4 construct cross-reacts with and shields against the GII.17 strain of norovirus in preclinical studies. Usually, GII.4 is the dominant strain behind most norovirus infection, yet a notable GII.17 outbreak occurred in late 2024 and carried on into 2025; we've already demonstrated strong cross-reactivity of our COVID-19 vaccine candidates against several SARS-CoV-2 variants, and the goal of these preclinical studies is to shed light on how useful our norovirus constructs might be against other norovirus strains, like GII.17. Being able to show that kind of cross-reactivity might boost both the utility and, as a result, the value of our norovirus vaccine program, since it would let our existing construct guard against a wider range of norovirus strains. We're eager to share the findings from these studies with you later in 2026. And should they be positive, we'll also fold them into the data package behind our partnership talks regarding this potentially first-in-class vaccine. I'll now turn the call over to Jeroen for a quick rundown of our financials. Jeroen?

Jeroen Grasman

executive
#5

Thanks, Sean. Today's press release lays out the specifics of our financial results for the fourth quarter and for the full year 2025. For the full year 2025, revenue came to $237.3 million, versus $28.7 million for the full year 2024. Most of the revenue in both the full year 2025 and the full year 2024 came from contracts tied to the BARDA contract that was awarded in June 2024, and 2025 additionally included revenue recognized from the Dynavax license and collaboration agreement signed in November 2025. Vaxart closed out the fourth quarter with $63.8 million in cash, cash equivalents and investments. Under our current plan, Vaxart anticipates a cash runway into the second quarter of 2027. Vaxart will stay aggressive in looking for strategic partnerships, chasing other non-dilutive funding options and keeping our expenses carefully managed so that we can extend our cash runway. At this point I'll hand the call back to Steve for closing remarks.

Steve Lo

executive
#6

Thank you, Jeroen. And once more, I appreciate all of you being with us today. We continue to feel quite positive regarding what our oral vaccine efforts for COVID-19 and norovirus could achieve, both in terms of significant public health gains and in generating shareholder value. For 2026, our key objectives involve completing the gathering and review of data from the COVID-19 clinical study and obtaining a partnership or alternative financing to move our norovirus initiative forward. We are eager to report top line findings from the 400-subject sentinel cohort within that COVID-19 trial during the early part of the second quarter of 2026, along with results from the 5,000 subject KP.2 cohort by the close of 2026. While our business development focus stays on the norovirus effort, we are simultaneously examining possible licensing or collaboration deals for our earlier-stage assets, such as the seasonal and pandemic flu candidates as well as our HPV program. In our view, the oral pill vaccine platform could serve as a disruptive technology capable of tackling public health issues and shifting personal attitudes toward vaccination. We are dedicated to unlocking the worth of this platform, and we are exploring multiple avenues to deliver that for our shareholders and for the numerous individuals who stand to gain from novel vaccines that meet unmet public and personal health requirements. Prior to opening the floor to your questions, I want to note for our audience that a webcasted fireside chat is scheduled for tomorrow, Friday, March 13, beginning at 4:30 p.m. Eastern Time. During that fireside chat, we anticipate covering additional frequently asked questions that stockholders have sent our way. As a reminder, written questions may be submitted to ir@vaxart.com. We will try to address as many of those as we can during the fireside chat. Because that fireside chat takes place tomorrow, no written questions will be accepted on today's call. Thank you all for spending time with us today. Operator, please open the line for questions.

Cheng Li

analyst
#7

Congratulations on the quarter. We have maybe two things. First off, regarding that data from the 400-person sentinel cohort, it appears there is probably a minor delay. As I understand it, the timing is now early in the second quarter versus what was previously guided, which was around late in the first quarter. So I'm curious if you can share any color on what changed? And then the follow-up is, how should we frame expectations now that the 400-person sentinel data <<inaudible>> through the complete Phase IIb data?

Steve Lo

executive
#8

Great. Cheng, thank you for those two questions; both are certainly suitable for Dr. Cummings. James will handle them. And yes, just to recognize, the earlier guidance pointed to the end of the first year, while the current guidance is early in the second quarter. And because James interacts a great deal with BARDA, he is able to give some — a bit more detail regarding the reasons, based on your question, and on the second question too.

James Cummings

executive
#9

Appreciate that, Steve. So what we'll be sharing is the 12-month top line results from our 400 participant cohort, and included in that will be information on the primary safety end points — which is exactly why that cohort exists, correct? It's a safety cohort. That's the reason it was set up that way, plus some early data on efficacy measures. Like I said, that 400-person cohort was built for safety, right? As for the 5,000-person KP.2 cohort, the data from it will give us some efficacy insights, and we expect to report those in the fourth quarter of 2026. Whenever we talk about putting out data, looking at data, and so on, those decisions get made together with our partners at BARDA. So they get a say in what gets delivered and when. That's why, working alongside them, I believe we're seeing a slight shift there. Over.

Steve Lo

executive
#10

Okay, and James, maybe you could handle the second one too — and also, in the same vein — you brought this up in your remarks as well, the possible read-through going from 400 up to roughly 5,000.

James Cummings

executive
#11

Right. That's what I was attempting to articulate. During Q2, some of the 400-person safety cohort ought to arrive; after that, the bigger and more solid data set covering the 5,000-person KP.2 cohort is going to deliver insights, including efficacy findings plus safety and immunogenicity. Top line data out of that should land initially — our projection is around Q4 of this year — with immunogenicity results probably arriving afterward.

Steve Lo

executive
#12

Thank you, James. Cheng, is there anything else you'd like to ask?

Cheng Li

analyst
#13

That covers everything I had.

Mayank Mamtani

analyst
#14

Okay, starting with the COVID program — clearly you've got several organizations involved, really significant vaccine players, BARDA plus Sanofi following a change of control. I'm curious what the decision points would look like for the next steps once you have that sentinel data in Q2 and the bigger, more robust data set in Q4? Also, just to verify, there's no immunogenicity data included in that Q2 update, correct? Then I have one short follow-up.

Steve Lo

executive
#15

Excellent. Mayank. Appreciate the question; let me take the first part, and then James can speak to what we expect to see in the sentinel 400. As a quick reminder for those listening, under the structure of our arrangement with BARDA as well as Dynavax, a Sanofi company, Vaxart and BARDA hold responsibility for the Phase IIb portion of the clinical trial. That means it remains under our oversight. Following the conclusion of Phase II, Dynavax would get the chance to make a decision once the end of Phase II package submitted to the FDA is finished, deciding whether to opt in or not; the good news, as I said before, is that we've had a fair amount of engagement with Dynavax, and things are progressing well; and naturally, we also have our engagement with BARDA. I'll hand it to James for additional comment on that and then also the — once more, the sentinel 400.

James Cummings

executive
#16

Absolutely. Steve, thank you, and Mayank, I appreciate the question. So as we examine those initial top line results, what we can deliver first is going to be the safety profile, the overall picture, and then some efficacy insights as well. When it comes to the immunogenicity data, that work is being handled at present mostly by our partners over at BARDA; executing that requires a bit more time; so it would come after that first batch of data, so to speak. That's what I expect, and not only for the sentinel 400, but in all likelihood for the KP.2 5,000-person cohort too.

Mayank Mamtani

analyst
#17

Got it. Then regarding the second-generation norovirus candidate, has any consistent feedback come in about the endpoint structures you might aim to assess in the upcoming Phase II trial? I suppose that's something for Sean or James to address.

James Cummings

executive
#18

Sure, Mayank, I'll handle that. So conversations have taken place between us and the FDA. The Phase IIb study's primary endpoint, as you're aware, is safety, correct? Therefore, we'll gather safety data from it, along with immunogenicity, and push that program ahead once — subject to securing a partner. Steve, anything else to add there?

Steve Lo

executive
#19

Yeah, I believe that's correct. Mayank, I'm not certain whether you have, like, another question to add. But just as James said, we've been in ongoing communication with the FDA regarding this study of ours.

Operator

operator
#20

That brings us to the end of both the Q&A portion and this teleconference for today, ladies and gentlemen. We appreciate everyone joining us. At this point you're free to hang up, and we hope the remainder of your day goes wonderfully.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.